Extraordinary General Meeting for Pharmexa A/S; Claus Braestrup New Chairman of the Board of Directors
August 21, 2002 09:58 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Aug. 21, 2002 (PRIMEZONE) -- On Wednesday, August 21, 2002 Pharmexa A/S held an extraordinary general meeting.
Claus Braestrup was elected to the Board of Directors. The Board of...
Pharmexa A/S: Interim Report for the First 6 Months of the Financial Year 2002
August 21, 2002 07:04 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Aug. 21, 2002 (PRIMEZONE) -- The Pharmexa Group had turnover of kDKK 8,123 in the first 6 months of 2002 and realized a net loss of kDKK 75,519. Research and Development costs...
Extraordinary General Meeting in Pharmexa A/S
August 05, 2002 07:09 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Aug. 5, 2002 (PRIMEZONE) -- Pursuant to article 8 of the Articles of Association the shareholders of Pharmexa A/S are hereby convened to the Extraordinary General Meeting on
...
New Warrant Program in Pharmexa
August 01, 2002 07:15 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, August 1, 2002 (PRIMEZONE) -- The board of directors in Pharmexa has approved a new warrant program to the employees and management group of the company. The warrant program...
Pharmexa -- Change of Financial Calendar 2002
July 30, 2002 09:50 ET
|
Pharmexa A/S
HORSHOLM, Denmark, July 30, 2002 (PRIMEZONE) -- The release of the interim financial report, H1 2002 scheduled for August 22, 2002 has been moved to August 21, 2002. Furthermore, Pharmexa is planning...
Inoxell and Rigel Enter Global Patent Settlement Agreement
June 24, 2002 07:08 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, June 24, 2002 (PRIMEZONE) -- Pharmexa's 83.33% owned subsidiary Inoxell A/S and Rigel Pharmaceuticals, Inc. today announced that the two companies have entered a global patent...
Progress in Clinical Trial with Pharmexa's AutoVac HER-2 DNA Pharmaccine for Breast Cancer
June 06, 2002 06:16 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, June 6, 2002 (PRIMEZONE) -- In July 2001 Pharmexa initiated a phase I/II clinical trial of the AutoVaca(TM) HER-2 DNA pharmaccine at clinical centers in Denmark for the treatment...
Pharmexa Receives Top Ranking in Danish Corporate Governance Award
May 29, 2002 07:35 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, May 29, 2002 (PRIMEZONE) -- The Danish Shareholders Association has announced the results of the Danish Corporate Governance Award 2002. The Award is based on 17 criteria around...
Pharmexa A/S: Interim Report for the First 3 Months of the Financial Year 2002
May 23, 2002 06:54 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, May 23, 2002 (PRIMEZONE) -- The Pharmexa Group had turnover of kDKK 4,893 in the first 3 months of 2002 and realised a net loss of kDKK 33,939. Research and Development costs...
Pharmexa Plans Clinical Trials in the U.S.A and Releases New Data from Its AutoVac HER-2 Protein Breast Cancer Product
May 21, 2002 06:41 ET
|
Pharmexa A/S
HARSHOLM, Denmark, May 21, 2002 (PRIMEZONE) -- Following a successful pre-IND meeting with the Food and Drug Administration (FDA) in the United States, Pharmexa has decided to conduct the first...